BIODEFENSE ANTIVIRALS AND ANTIBIOTICS 

Release Date:  June 13, 2002

NOTICE:  NOT-AI-02-029

National Institute of Allergy and Infectious Diseases (NIAID)
 (http://www.niaid.nih.gov)

Receipt Date for Letter of Interest: July 12, 2002

The National Institute of Allergy and Infectious Diseases (NIAID) wishes to 
expedite development of two classes of currently licensed and marketed drugs for 
treatment of potential agents of bioterrorism: (1) Antiviral drugs for treatment
of viral hemorrhagic fevers, and (2) Antibiotics for treatment of anthrax, 
pneumonic plague, and tularemia.

NIAID is interested in receiving letters of interest regarding screening, 
development, and future licensure from organizations that have candidate drugs 
and the needed research capabilities. Interested organizations should submit a 
letter of interest that contains a detailed description of their potential 
development plans, and their R&D capabilities and interest. The letter of 
interest along with any supporting documentation shall not exceed 10 pages. 
Letters of interest will be kept confidential and will help in determining the 
need for an RFP to support further development, testing, and licensure of these 
products, and in assembling a potential source list for distribution if an RFP
is issued.

INQUIRIES

Submit your response to the address listed below:

Barbara A. Shadrick
Senior Contracting Officer
Contract Management Branch, DEA
National Institute of Allergy and Infectious Diseases, NIH
6700-B Rockledge Drive, Room 2230, MSC 7612
Bethesda, MD  20892-7612 
Phone:  301-496-7288
Fax:  301-480-5253 or 301-402-0972
E-Mail:  bs92y@nih.gov

Return to Volume Index

Return to NIH Guide Main Index

	Office of Extramural Research (OER)			National Institutes of Health (NIH) 9000 Rockville Pike Bethesda, Maryland 20892			Department of Health and Human Services (HHS)
Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see Help Downloading Files.